Pfizer's new COVID vaccine shows promising results with 4x immunity boost, but Kennedy's restrictions leave most Americans ...
Pfizer PFE is due to report third-quarter 2025 results on Nov. 4. All eyes will be on sales of Pfizer’s oncology drugs, which account for more than 25% of the company’s total revenues. Pfizer’s key ...
Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth ...
In August, the U.S. Food and Drug Administration approved the new COVID-19 booster shots, but with certain restrictions.
The market for VZV infection treatment is driven by increased vaccination and antiviral use, rising elderly populations, and strong immunization programs in developed regions. Key opportunities ...
It’s that time of year when the leaves are turning golden, there’s a chill in the air and the threat of respiratory viruses ...
QSM Asset Management added 276,899 shares of Pfizer for an estimated $6.8 million in the third quarter. After the transaction ...
Key Points Sold entire holding of 109,630 shares; estimated trade value of approximately $2.66 million based on the quarterly average price Stake was previously 1.2% of fund AUM as of the prior ...
The mRNA therapeutics market offers key opportunities in developing vaccines and treatments for chronic and infectious diseases, driven by successful clinical trials and increased government and ...
After weeks of confusion, approval by CDC and its acting director mean most Nebraskans can get COVID-19 vaccines after consulting with a health care provider, including pharmacists.
The U.S. pharmaceutical industry needs to collaborate with China, given the country's relatively faster drug development, ...
Americans headed to pharmacies for COVID-19 vaccines are running into roadblocks and confusion due to new U.S. guidance that ...